Basal cell carcinoma: electrochemotherapy, surgery show similar recurrence outcomes

  • Eur J Surg Oncol

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Electrochemotherapy (ECT) is associated with a similar recurrence rate as surgery in patients with basal cell carcinoma, according to a randomized controlled trial.

Why this matters

  • ECT appears to represent a viable alternative for patients with BCC.

Key results

  • ECT was associated with a 100% response rate (12% of patients needed a second treatment to ensure complete response).
  • Surgery was associated with a 100% complete excision rate on histology (5% of patients needed a second excision).
  • Surgery and ECT were associated with similar recurrence rates (1.9% vs 7.5%; P=.33) in intention-to-treat analysis.

Study design

  • 100 patients with BCC were randomly assigned: 52 to ECT and 48 to surgery.
  • 87 patients, 45 treated with ECT and 42 treated with surgery, were treated and followed up at 6 months.
  • Funding: Breakthrough Cancer Research.

Limitations

  • Small patient sample size.